Division of Cancer Biology Home Page Office of the Director Cancer Cell Biology Branch Cancer Etiology Branch Cancer Immunology and Hematology Branch DNA and Chromosome Aberrations Branch Structural Biology and Molecular Applications Branch Tumor Biology and Metastasis Branch Integrative Cancer Biology Program Mouse Models of Human Cancer Consortium Tumor Microenvironment Network
Definitive Full Year NCI Funding Policy For FY2003

 

 Announcements / News

Definitive Full Year NCI Funding Policy For FY2003


  • Non competing (Type 5) continuations (all mechanisms)
  • All non-competing continuation awards will be paid at full committed levels on their regular anniversary dates.

  • Competing RO1s
  • Retroactive to the September, 2002 National Cancer Advisory Board round (the first funding cycle of FY 2003), new (type 1) and competing continuation (type 2) R01 applications up to the 20.0 percentile will be paid within the payline. Non-percentiled R01s will be paid on a case by case basis. All prior competing R01 awards previously paid within FY 2003 interim paylines will be restored to standard policy levels, where possible.

  • New (Type 1) Competing RO1 applications from first time RO1 investigators
  • Applicants eligible for consideration as first time R01 investigators will be paid at a pay line of the 23.0 percentile).

  • Program project (P01) applications (new and competing continuation)
  • P01s will continue to be paid on a case by case basis. P01 applicants will be notified of their status by the NCI program staff.

  • Amended applications (all mechanisms)
  • Applicants who are not eligible for funding under this plan should submit an amended application for the June/July (or next regular) receipt date. Such applications, along with those submitted for the February/March, 2003 receipt date, will be funded under FY 2004 budget plans, which are not yet known and may be different from these FY 2003 announced levels.

  • Requests For Applications (RFAs)
  • NCI is committed to the review and funding of all RFAs that have been previously announced and solicited for competition and award in FY 2003. As always, success rates for RFAs depend on the number and quality of the applications received, and applications are considered for payment on a case by case basis. Please consult the program director listed on your summary statement if you have any questions regarding these competitions.

  • Budget Reductions
  • To achieve the above paylines it is necessary to require modest budget reductions of competing awards from approved requested levels. For type 1 modular R01s of 7 units or less within the payline, this will generally be 5%. For type 1 larger R01s, it will be a reduction of 11%. R01s designated as MERIT Awards will be exempt from these reductions. Program project awards are adjusted on a case by case basis, with type 1 awards averaging a 15% reduction. Type 2 larger R01s and all P01 awards in conformance with NCI budget cap policies will be subject to a 6% reduction on average.

  • General Questions
  • The NCI website lists additional information and history under "funding policies": http://www.nci.nih.gov/research_funding/policies.


National Cancer InstituteNational Cancer Institute (NCI) National Institutes of HealthNational Institutes of Health (NIH) Health & Human ServicesDepartment of Health & Human Services (DHHS) First Gov
Related
Links

 

Division of Cancer Biology Home PageThe National Cancer Institute (Cancer.gov)

     Help | Contact Us | Accessibility

National Cancer Institute U.S. Department of Health & Human Services National Institutes of Health USA.gov